Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude de CAP-1002 chez des patients ambulatoires et non ambulatoires atteints de dystrophie musculaire de Duchenne (HOPE-3)

11 novembre 2026 mis à jour par: Capricor Inc.

Un essai de phase 3, randomisé, en double aveugle et contrôlé par placebo évaluant l'efficacité et l'innocuité des cellules allogéniques humaines dérivées de la cardiosphère pour le traitement de la dystrophie musculaire de Duchenne

HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either deramiocel or placebo every 3 months for a total of 4 doses during the first 12 months of the study. All participants will be eligible to receive 4 doses of deramiocel for an additional 12 months as part of an open-label extended assessment period. After completion of the first open-label extension (Months 12-24), subjects who have completed Month 24 are eligible to continue onto a Long-Term Open-Label Extension period that will provide treatment with deramiocel until commercial availability, or until sponsor's decision to terminate the trial, or the participant withdraws consent.

Aperçu de l'étude

Description détaillée

Up to 102 eligible study subjects will participate in this two cohort study. Cohort A will enroll approximately 58 subjects randomized in a 1:1 ratio (active:placebo). Subjects randomized to the active treatment group in Cohort A will receive CAP-1002A (deramiocel manufactured at Capricor's manufacturing facility in Los Angeles, CA). Once Cohort A enrollment is completed, Cohort B enrollment will begin. Cohort B will enroll approximately 44 participants randomized in a 1:1 ratio (active:placebo). Subjects randomized to the active treatment group in Cohort B will receive CAP-1002B (deramiocel manufactured at Capricor's manufacturing facility in San Diego, CA). Both cohorts will include visits at Screening, Baseline/Day 1, Month 1, and Months 3, 6, 9, and 12. Subjects will receive IV infusions of deramiocel or placebo on Day 1 and Months 3, 6, and 9. All subjects will then be eligible to receive additional IV infusions of deramiocel at Month 12, 15, 18, and 21 as part of the open-label phase of the study. All subjects who complete the first open-label extension phase of the study will be eligible to receive additional IV infusions of deramicoel every 3 months in a Long Term Open-Label Extension phase until commercial availability of deramiocel, or until sponsor's decision to terminate the trial, or the participant withdraws consent.

A primary analysis of efficacy and safety will be performed on the double-blind placebo-controlled phase of the study for both Cohort A and Cohort B combined at Month 12 following 4 administrations of deramiocel or placebo.

The primary efficacy endpoint is the mean change from baseline in upper limb function as assessed by Performance of the Upper Limb test, version 2.0 [PUL 2.0] Total Score at the 12-month time point. Secondary endpoints evaluated at the 12-month time point include assessment of changes in cardiac muscle function and structure by cardiac magnetic resonance imaging [cMRI], changes in hand-to-mouth function [eat 10-bites assessed by the Duchenne Video Assessment (DVA)], quality of life assessments, and biomarker analysis for creatine kinase MB isoenzyme (CK-MB).

Safety evaluations will include adverse events, concomitant medications, physical exam, vital signs, and clinical laboratory testing.

An analysis of extended safety and efficacy will be performed in the subsequent open-label phases of the study.

Type d'étude

Interventionnel

Inscription (Réel)

106

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Arizona
      • Phoenix, Arizona, États-Unis, 85016
        • Phoenix Children's Hospital
    • Arkansas
      • Little Rock, Arkansas, États-Unis, 72202
        • Arkansas Children's Hospital
    • California
      • La Jolla, California, États-Unis, 92037
        • UCSD Altman Clinical and Translational Research Institute
      • Los Angeles, California, États-Unis, 90027
        • Children's Hospital of Los Angeles, Division of Neurology
      • Sacramento, California, États-Unis, 95817
        • University of California, Davis
    • Colorado
      • Aurora, Colorado, États-Unis, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, États-Unis, 30329
        • Rare Disease Research, LLC
    • Illinois
      • Chicago, Illinois, États-Unis, 60611
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Iowa
      • Iowa City, Iowa, États-Unis, 52242
        • University of Iowa Hospitals and Clinics
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Boston Children's Hospital
    • Missouri
      • Columbia, Missouri, États-Unis, 65212
        • University of Missouri Health Care
      • St Louis, Missouri, États-Unis, 63110
        • Saint Louis Children's Hospital
    • North Carolina
      • Hillsborough, North Carolina, États-Unis, 27278
        • Rare Disease Research NC LLC
    • Ohio
      • Akron, Ohio, États-Unis, 44308
        • Akron Children's Hospital
      • Cincinnati, Ohio, États-Unis, 45229
        • Cincinnati Children's Hospital Medical Center
    • Texas
      • Dallas, Texas, États-Unis, 75207
        • Children's Health Specialty Care Pavilion
    • Utah
      • Salt Lake City, Utah, États-Unis, 84112
        • University of Utah Hospital
    • Virginia
      • Charlottesville, Virginia, États-Unis, 22903
        • University of Virginia Children's Hospital
    • Washington
      • Seattle, Washington, États-Unis, 98105
        • Seattle Children's
    • Wisconsin
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Children's Wisconsin

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

10 ans et plus (Enfant, Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Homme

La description

Inclusion Criteria:

  1. Male subjects at least 10 years of age at time of consent who are willing and able to provide informed consent to participate in the trial if ≥ 18 years of age or assent with parental or guardian informed consent if < 18 years of age. If a third-party caregiver is involved, they must provide informed consent.
  2. Diagnosis of DMD based on clinical and phenotypic manifestations consistent with DMD (e.g., family history of DMD, elevated creatine kinase, dystrophin muscle biopsy, calf pseudohypertrophy, history of Gowers' sign, and gait impairment before 7 years of age) as confirmed by the Investigator.
  3. Confirmatory genetic testing performed to have reached a diagnosis of DMD at any time in the past or currently performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or equivalent.
  4. Performance of the Upper Limb test (PUL) entry item scores 2-6 and total PUL score less than or equal to 40. For Cohort A only: enrollment of patients with PUL entry score 6, Exon 44 skipping amenable, and/or Exon 3 through 7 deletions will be capped at no more than 10% of the total study population (approximately 6 patients with these characteristics).
  5. Reduced ability to walk/run (if ambulatory): subjects must take more than 10 seconds for the 10-meter walk/run (i.e., velocity < 1 meter/second).
  6. If non-ambulatory, loss of independent ambulation between 10th and 18th year birthday (standing unassisted or ability to take, at most, several steps independently is not considered ambulation). Subjects who are considered non-ambulatory between the ages of 9 and10 may be enrolled with prior approval from the sponsor.
  7. Receiving standard of care therapy at an experienced, multidisciplinary DMD center as evidenced by regular cardiac and pulmonary monitoring, systemic glucocorticoid treatment, and at-home range of motion exercises.
  8. Treatment with systemic glucocorticoids for at least 12 months and at a stable dose at least 6 months prior to study participation, except for either weight-based dose adjustment or a decrease in steroid dose of ≤ 10% for toxicity. For patients on chronic deflazacort, treatment with an equivalent dose of prednisone or prednisolone for a period of ≤ 30 days to bridge lack of availability of deflazacort during the 6 months prior to randomization is acceptable.
  9. Current and up-to-date immunizations according to children and adolescent Centers for Disease Control and Prevention immunization schedule at the discretion of the Investigator.
  10. Adequate venous access for parenteral IP infusions and routine blood collection.
  11. Assessed by the Investigator as willing and able to comply with the requirements of the trial.
  12. Sexually active subjects and their partners who are fertile must agree to use effective method(s) of contraception.

Exclusion Criteria:

  1. Left ventricular ejection fraction (LVEF) less than or equal to 35% prior to randomization.
  2. Elbow-flexion contractures > 30° in both extremities.
  3. Body mass index (BMI) > 45.
  4. Percent predicted forced vital capacity (FVC%) < 35% within 6 months prior to randomization.
  5. Inability to perform consistent PUL 2.0 measurement within ± 2 points without shoulder domain or within ± 3 points with shoulder domain during paired testing at screening.
  6. Risk of near-term respiratory decompensation in the judgment of the Investigator, or the need for initiation of day and night non-invasive ventilator support as defined by serum bicarbonate ≥ 29 mmol/L at screening.
  7. History of non DMD-related chronic respiratory disease requiring ongoing or intermittent treatment, including, but not limited to, asthma, bronchitis, and tuberculosis.
  8. Acute respiratory illness within 30 days prior to screening and during screening.
  9. Initiation of nocturnal non-invasive ventilation within 30 days prior to screening.
  10. Planned or anticipated thoracic or spinal surgery within the 6 months following randomization.
  11. Planned or anticipated lower extremity surgery within the 6 months following randomization, if ambulatory.
  12. Known hypersensitivity to dimethyl sulfoxide (DMSO) or bovine products.
  13. Initiation of treatment with metformin or insulin within 3 months prior to randomization.
  14. Initiation of treatment with an FDA-approved exon skipping therapy for the treatment of DMD and/or non-weight based adjustments within 12 months prior to randomization.
  15. Treatment with human growth hormone within 3 months prior to randomization, unless on a stable dose allowing for weight-based dose adjustments (as determined by the site Investigator) for at least 24 months prior to randomization.
  16. Treatment with a cell therapy product within 12 months prior to randomization; any prior exposure to deramiocel will be excluded.
  17. Treatment with an investigational product within 6 months prior to randomization.
  18. History, or current use, of drugs or alcohol that could impair the ability to comply with participation in the trial.
  19. Inability to comply with the investigational plan and follow-up visit schedule for any reason, in the judgment of the investigator.
  20. Inability to undergo a cardiac MRI. For Cohort B Only - Subjects with a known hypersensitivity to gadolinium may forgo the LGE assessment but must complete a cardiac MRI without contrast. For Cohort B Only - Subjects who are unable to tolerate gadolinium due to renal insufficiency as measured by an estimated Glomerular Filtration Rate (eGFR) less than 60 mL/min/1.73 m2 may forgo the LGE assessment but must complete a cardiac MRI without contrast.
  21. For Cohort B: Subjects with PUL entry score 6, Exon 44 skipping amenable, or Exon 3 through 7 deletions are excluded from participation.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Deramiocel (CAP-1002) Cohort A

Cohort A: Approximatetly 29 subjects will receive deramiocel (CAP-1002A) active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 infusions through Month 12 of the study

Cardiosphere-Derived Cells (CDCs)

Autres noms:
  • CAP-1002

Cardiac magnetic resonance imaging is performed to assess cardiac function

Autres noms:
  • IRMc
Comparateur placebo: Placebo Cohort A

Cohort A: Approximately 29 subjects will receive a Placebo solution via intravenous infusion every 3 months for a total of 4 infusions through Month 12 of the study

Placebo

Cardiac magnetic resonance imaging is performed to assess cardiac function

Autres noms:
  • IRMc
Expérimental: Deramiocel (CAP-1002) Cohort B

Cohort B: Approximately 22 participants will receive deramiocel (CAP-1002B) active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 infusions through Month 12 of the study

Cardiosphere-Derived Cells (CDCs)

Autres noms:
  • CAP-1002

Cardiac magnetic resonance imaging is performed to assess cardiac function

Autres noms:
  • IRMc

Cardiac magnetic resonance imaging with contrast to assess late gadolinium enhancement (LGE) in Cohort B participants

Autres noms:
  • cMRI with contrast
Comparateur placebo: Placebo Cohort B

Cohort B: Approximately 22 participants will receive a Placebo solution via intravenous infusion every 3 months for a total of 4 infusions through Month 12 of the study

Placebo

Cardiac magnetic resonance imaging is performed to assess cardiac function

Autres noms:
  • IRMc

Cardiac magnetic resonance imaging with contrast to assess late gadolinium enhancement (LGE) in Cohort B participants

Autres noms:
  • cMRI with contrast
Expérimental: Deramiocel (CAP-1002) Open Label Extension

Open-Label Extension: After completion of the double-blind, placebo-controlled phase, subjects will receive deramiocel (CAP-1002) active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for an additional 12 months followed by the long-term open label extension phase which continues deramiocel administration every 3 months until sponsor decision.

Cardiosphere-Derived Cells (CDCs)

Autres noms:
  • CAP-1002

Cardiac magnetic resonance imaging is performed to assess cardiac function

Autres noms:
  • IRMc

Cardiac magnetic resonance imaging with contrast to assess late gadolinium enhancement (LGE) in Cohort B participants

Autres noms:
  • cMRI with contrast

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in the upper limb function
Délai: At Month 12

Mean percent change from baseline in Performance of the Upper Limb test, version 2 (PUL 2.0) Total Score. Items are scored on a three-point scale: 0=unable to perform the item, 1=impaired or performs with compensation, 2=performs task without compensation. Percent change from baseline is calculated as change from baseline divided by baseline score at the subject level.

At Month 12

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in cardiac muscle function and structure by assessment of left ventricular ejection fraction
Délai: At Month 12

Mean change from baseline in left ventricular ejection fraction as assessed by Cardiac Magnetic Resonance (cMRI) and assessed centrally

At Month 12
Change in mid-level (elbow) upper limb function
Délai: At Month 12

Mean percent change from baseline in mid-level [elbow] upper limb function in Performance of the Upper Limb test, version 2 (PUL 2.0); items are scored on a three-point scale: 0=unable to perform the item, 1=impaired or performs with compensation, 2=performs task without compensation. Percent change from baseline is calculated as change from baseline divided by baseline score at the subject level.

At Month 12
Change in Global Statistical Test (Total GST) combining upper limb function, cardiac muscle function, and patient reported measure of disease severity
Délai: At Month 12

Mean change from baseline in Total GST that combines PUL 2.0 score, LVEF assessment by cMRI, and the Patient Global Impression of Severity (PGI-S)

At Month 12
Change in the number of segments of myocardial scarring (Cohort B only)
Délai: at Month 12

Change in the number of segments of myocardial scarring as observed by late gadolinium enhancement (LGE)

at Month 12
Change in cardiac muscle function and structure by assessment of left ventricular end-systolic volume
Délai: At Month 12

Mean change from baseline in left ventricular indexed end-systolic volume as assessed by Cardiac Magnetic Resonance (cMRI)

At Month 12
Change in cardiac muscle function and structure by assessment of left ventricular ejection fraction in subjects with documented cardiomyopathy
Délai: At Month 12

Mean change from baseline in left ventricular ejection fraction as assessed by Cardiac Magnetic Resonance (cMRI) in subjects with documented cardiomyopathy at baseline.

At Month 12
Change in a global statistical test (Cardiac GST) combining assessments of cardiac muscle function and structure
Délai: At Month 12

Mean change from baseline in Cardiac GST that combines LVEF, LV end-systolic volume index, and LV end-diastolic volume index

At Month 12
Change in percentage of myocardial scarring (Cohort B only)
Délai: at Month 12

Change in percentage of myocardial scarring as observed by late gadolinium enhancement (LGE)

at Month 12
Change in hand-to-mouth function in the context of functional eating
Délai: At Month 12

Mean change from baseline in the functional ability of eating 10 bites evaluated by Duchenne Video Assessment (DVA) using a video record of patient performing the task at home. Physical therapists score the patient's quality of movement in the video using scorecards with pre-specified compensatory movement criteria.

At Month 12
Changes in cardiac inflammation biomarker, creatine kinase MB isoenzyme [CK-MB]
Délai: At Month 12

Mean change from baseline in CK-MB blood levels - MB fraction (% of total CK).

At Month 12

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Mark Awadalla, Capricor Inc.
  • Chercheur principal: Craig McDonald, MD, University of California, Davis

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

22 juin 2022

Achèvement primaire (Réel)

18 juin 2025

Achèvement de l'étude (Estimé)

1 mars 2027

Dates d'inscription aux études

Première soumission

4 novembre 2021

Première soumission répondant aux critères de contrôle qualité

16 novembre 2021

Première publication (Réel)

19 novembre 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner